Search

Your search keyword '"Stoker N"' showing total 772 results

Search Constraints

Start Over You searched for: "Stoker N" Remove constraint "Stoker N"
772 results on '"Stoker N"'

Search Results

101. MOLECULAR DIAGNOSIS OF BRUCELLA ABORTUS FROM CLINICAL SAMPLES OF CATTLE AND BUFFALOES.

102. Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations.

103. HupB, a nucleoid-associated protein, is critical for survival of Mycobacterium tuberculosis under host-mediated stresses and for enhanced tolerance to key first-line antibiotics.

104. Compilation of 10 Years of MIRU-VNTR Data: Canadian National Tuberculosis Laboratory's Experience.

105. Human Pulmonary Tuberculosis: Understanding the Immune Response in the Bronchoalveolar System.

106. Brucellosis re‐emergence after a decade of quiescence in Palestine, 2015–2017: A seroprevalence and molecular characterization study.

107. Field evaluation of specific mycobacterial protein‐based skin test for the differentiation of Mycobacterium bovis‐infected and Bacillus Calmette Guerin‐vaccinated crossbred cattle in Ethiopia.

108. The Orphan Response Regulator Rv3143 Modulates the Activity of the NADH Dehydrogenase Complex (Nuo) in Mycobacterium tuberculosis via Protein–Protein Interactions.

109. An Evolutionary Conservation and Druggability Analysis of Enzymes Belonging to the Bacterial Shikimate Pathway.

111. A Novel Acyl-AcpM-Binding Protein Confers Intrinsic Sensitivity to Fatty Acid Synthase Type II Inhibitors in Mycobacterium smegmatis.

112. ДІЯЛЬНІСТЬ ВОЄННО-ІНСТРУКТОРСЬКИХ МІСІЙ ЄВРОПЕЙСЬКИХ КРАЇН І США В АРМІЯХ ДЕРЖАВ, ЩО РЕФОРМУВАЛИ ЗБРОЙНІ СИЛИ (ОСТАННЯ ТРЕТИНА ХІХ – ПЕРША ТРЕТИНА ХХ СТ.): ПРОБЛЕМИ ТА ПЕРСПЕКТИВИ ДОСЛІДЖЕНЬ.

113. Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.

114. Experimental Evolution Reveals Redox State Modulates Mycobacterial Pathogenicity.

116. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.

117. Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases.

118. Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review.

119. Bio-oil production from oleaginous microorganisms using hydrothermal liquefaction: A biorefinery approach.

120. Proteomics-based screening and antibiotic resistance assessment of clinical and sub-clinical Brucella species: An evolution of brucellosis infection control.

121. Public health and hospital‐based nursing intersection: Case study of drug‐resistant tuberculosis patients.

122. Galleria mellonella as a Suitable Model of Bacterial Infection: Past, Present and Future.

123. A conserved membrane protein negatively regulates Mce1 complexes in mycobacteria.

124. Alginate-Capped Silver Nanoparticles as a Potent Anti-mycobacterial Agent Against Mycobacterium tuberculosis.

125. Global survey-based assessment of lifestyle changes during the COVID-19 pandemic.

126. Role of the kdpDE Regulatory Operon of Mycobacterium tuberculosis in Modulating Bacterial Growth in vitro.

127. A Novel Close-tube Loop Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of Brucella.

128. Comparison of PCR and Conventional Serological Methods for Detection of Brucella spp. in Ovine and Caprine Blood Serum.

129. Genetic Manipulation of Non-tuberculosis Mycobacteria.

130. RegX3-Mediated Regulation of Methylcitrate Cycle in Mycobacterium smegmatis.

131. Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era.

132. Re-sensitization of Mycobacterium smegmatis to Rifampicin Using CRISPR Interference Demonstrates Its Utility for the Study of Non-essential Drug Resistance Traits.

133. Understanding the impact of climate change on the oceanic circulation in the Chilean island ecoregions.

134. The Syndemics and Structural Violence of the COVID Pandemic: Anthropological Insights on a Crisis.

135. Small Noncoding RNAs MTS0997 and MTS1338 Affect the Adaptation and Virulence of Mycobacterium tuberculosis.

136. Methods for Detecting Mycobacterial Mixed Strain Infections–A Systematic Review.

137. Characterization of the Mycobacterial MSMEG-3762/63 Efflux Pump in Mycobacterium smegmatis Drug Efflux.

138. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

139. Comparison of loop-mediated isothermal amplification and conventional PCR tests for diagnosis of common Brucella species.

140. SiCTeC: An inexpensive, easily assembled Peltier device for rapid temperature shifting during single-cell imaging.

141. A Glutamine Insertion at Codon 432 of RpoB Confers Rifampicin Resistance in Mycobacterium tuberculosis.

142. Contribution of 3D printing technology for craniofacial surgery.

143. The tryptophan biosynthetic pathway is essential for Mycobacterium tuberculosis to cause disease.

144. BRUCELLOSIS: CURRENT STATUS OF THE DISEASE AND FUTURE PERSPECTIVES.

145. RegX3 Activates whiB3 Under Acid Stress and Subverts Lysosomal Trafficking of Mycobacterium tuberculosis in a WhiB3-Dependent Manner.

146. The Two-Component Locus MSMEG_0244/0246 Together With MSMEG_0243 Affects Biofilm Assembly in M. smegmatis Correlating With Changes in Phosphatidylinositol Mannosides Acylation.

147. Genetic Diversity and Phylogenetic Relationship of Clinical Isolates of Brucella melitensis Based on Gene Polymorphism of β Subunit of RNA Polymerase (rpoB) Gene in Iran.

150. Integrated Quantitative Proteomics and Metabolome Profiling Reveal MSMEG_6171 Overexpression Perturbing Lipid Metabolism of Mycobacterium smegmatis Leading to Increased Vancomycin Resistance.

Catalog

Books, media, physical & digital resources